Moderna gets a boost from data in older subjects and a potential logistical advantage.
The Covid-19 pandemic has scythed vast sums from joint makers’ Q2 sales. But Medtronic’s summer earnings were better than those for its spring quarter.
The FDA’s emergency use authorisation for plasma for Covid-19 looks questionable. If this presages an early vaccine nod, we should be very afraid.
Pfizer/Biontech’s preprint might prove academic as investors look to pivotal study designs and readouts.
Curevac’s market cap has ballooned almost fivefold since floating, sending the mRNA company into the record books.
Qiagen is one of the few medtechs to do well out of the Covid-19 pandemic. From Thermo Fisher’s point of view it has done too well.
The new price for its Covid-19 vaccine is lower than earlier deals – but arguably not by much.